10-Q quarterly report · filed Nov 9, 2026

Bicara Therapeutics Inc. (BCAX) Q3 2026 10-Q Quarterly Report

Short answer

Bicara Therapeutics Inc. (BCAX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$71M
−96.1% YoY · −28.5% QoQ
EPS (diluted)
−$1.05
−59.1% YoY · −31.3% QoQ

Source: XBRL data from the Bicara Therapeutics Inc. (BCAX) Q3 2026 10-Q on SEC EDGAR. USD.

Bicara Therapeutics Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no product sales or other revenue generated
  • Net loss $71.2M vs $36.3M YoY, operating expenses $75.7M vs $40.7M
  • R&D highest spending area: $56.5M vs $33.0M, driven by FORTIFI-HN01 and FORTIFI-FLEX
  • Cash, equivalents and marketable securities $442.3M; operating cash use $137.8M vs $82.9M
  • February offering added $161.8M; funding expected into first half of 2029, additional capital needed thereafter

Risk Factors

  • No explicit new risk factor identified versus the 10-K; filing presents existing risks without a change statement
  • Financial: $442.3 million cash, equivalents and marketable securities projected to fund operations into first half of 2029
  • Regulatory: BIOSECURE Act restrictions could impair supply from Chinese biotechnology partners, with prohibitions expected in 2027 at earliest
  • Operational: Reliance on WuXi Biologics for ongoing clinical supply creates concentration risk amid China-U.S. geopolitical tensions
  • Clinical: Ficerafusp alfa’s Phase 2/3 FORTIFI-HN01 trial faces enrollment, safety and regulatory approval uncertainty

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Bicara Therapeutics Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.